Alzheimer's Disease Diagnostic Recent Treatment Strategies and Market Trends

The types studied in the global alzheimer's diagnostic market are early-onset alzheimer's, late-onset alzheimer's and familial alzheimer's disease.
 
WILMINGTON, Del. - June 30, 2022 - PRLog -- There has been an exponential rise in the number of cases of Alzheimer's disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer's Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected with Alzheimer's disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. Similarly, according to alzheimer's disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer's diagnostics worldwide.
  • Alzheimer's Disease Diagnostic Market Outlook
  • Alzheimer's Disease Diagnostic Market Regional Trends
  • Alzheimer's Disease Diagnostic Market Segmental Highlights

ALZHEIMER'S DISEASE DIAGNOSTIC MARKET KEY PLAYERS

The key companies in the alzheimer's diagnostic market (https://www.axiommrc.com/product/10046-alzheimer-s-diseas...) are Axon Neuroscience, Koninklijke Philips N.V., TauRx, Siemens AG, F. Hoffmann La Roche AG, GE Healthcare, navidea biopharmaceuticals, Treventis Corporation, Eli Lilly, Cognition Therapeutics Inc. and Neuro-Bio Ltd (UK). Foremost companies have invested huge capital in mergers & acquisitions and research & development activities to develop advanced products in the market.

ALZHEIMER'S DISEASE DIAGNOSTIC MARKET DEVELOPMENT

March 2020: GE Healthcare completed the transfer of ownership of its four diagnostic imaging agents in Japan from Daiichi Sankyo Company, Limited. Effective immediately, the four imaging agents, previously managed by Daiichi Sankyo, will be owned and managed by GE Healthcare Pharma Limited, which will now be responsible for all aspects of their commercialization for Japanese hospitals and clinics.

March 2018: Philips introduces new Ingenia Elition MRI solution. The latest solution is designed to offer high-quality patient-centric images with up to 50% faster exam process for enhanced patient experience and improved care. Ingenia Elition features the new patient sensing technology and SmartExam analytics powered by artificial intelligence (AI) to automate planning, scanning and processing of MR exams for optimised workflow.

Get Sample Copy Of This Analysis Report:

https://www.axiommrc.com/request-for-sample/10046-alzheimer-s-disease-diagnostic-market-report

Contact
Axiom Market Research & Consulting
***@axiommarketresearch.com
End
Email:***@axiommarketresearch.com Email Verified
Tags:Alzheimers Disease
Industry:Health
Location:Wilmington - Delaware - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share